ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Abstract Number: 2094

Increasing Collaboration, Education, and Awareness of Scleroderma Through an Interprofessional Education Program: Emphasizing the Importance of a Multidisciplinary Team and the Patient as the Primary Educator
Abstract Number: 2095

Integrated Analysis of Gene Expression and Methylation Identifies Biomarkers Associated with Mode of Action of Upadacitinib Treatment in Rheumatoid Arthritis
Abstract Number: 2096

Association of Left Ventricular Mass with Interleukin-17 in Rheumatoid Arthritis Patients Without Clinical Heart Failure
Abstract Number: 2097

Comparing the World Health Organization and the American College of Cardiology/American Heart Association Algorithms for Detection of Carotid Plaque
Abstract Number: 2098

Contribution of Rare Deleterious Exonic Variants in Telomere Related Genes to Interstitial Lung Disease Risk in Patients with Rheumatoid Arthritis
Abstract Number: 2099

Lesser Impact of Lower-Small Joint Involvement on Pain Than Upper-Small Joint in Rheumatoid Arthritis: Analysis Based on a Large Rheumatoid Arthritis Database in Japan
Abstract Number: 2100

Paradoxical Antagonistic Association of Visceral and Subcutaneous Adipose Tissue with Circulating C-Reactive Protein in Rheumatoid Arthritis
Abstract Number: 2101

Diagnosis of Mental Disorder Complicated by Rheumatoid Arthritis: A Study of the Validity of a Psychiatrist’s Diagnosis and Questionnaire Method
Abstract Number: 2102

Is This Prosthetic Joint Infected or Flaring?
Abstract Number: 2103

Inflammation and Immunomodulatory Therapies Influence the Relationship Between ATP-binding Cassette Transporter A1 (ABCA1)-mediated Cholesterol Efflux and Coronary Atherosclerosis in Rheumatoid Arthritis
Abstract Number: 2104

Relationship Between Frailty and Large Joint Symptoms in Rheumatoid Arthritis Patients
Abstract Number: 2105

Cohort-wide Immuno-phenotype Deconvolute Immunological and Clinical Heterogeneity Across Autoimmune Rheumatic Diseases
Abstract Number: 2106

Evaluation of the Construct of Constitutional Stiffness (CS) in Anti-CCP-Antibody-Positive Rheumatoid Arthritis (ACPA+RA) and Controls
Abstract Number: 2107

Social Determinants of Health and Clinical Outcomes in Rheumatoid Arthritis: A Single Center Study
Abstract Number: 2108

Specific Symptom Clusters at Diagnosis Signal a Poorer Early RA Prognosis: Data from the Canadian Early Arthritis Cohort (CATCH)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].